Calcein-effluxing human colon cancer cells are enriched for selfrenewal capacity and depend on β-catenin

Oncotarget

Volumn 4, Issue 2, 2013, Pages 184-191

  Allen, Joshua E ^a   El Deiry, Wafik S ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

Beta catenin; Calcein; Cancer stem cell; CloP; Colon cancer; Side population; Wnt

Indexed keywords

BETA CATENIN; CALCEIN; CD133 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; SMALL INTERFERING RNA; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL RENEWAL; CELL SUBPOPULATION; COLON CANCER; CONTROLLED STUDY; ENRICHMENT CULTURE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84875784975     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.883     Document Type: Article

References (31)

1. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St. Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. The Journal of Clinical Investigation. 2008; 118(6):2111-2120.
2. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM. Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. Cancer Research. 2009; 69(8):3382-3389.
3. Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW and Huang EH. Aldehyde Dehydrogenase-Expressing Colon Stem Cells Contribute to Tumorigenesis in the Transition from Colitis to Cancer. Cancer Research. 2009; 69(20):8208-8215.
4. Moserle L, Ghisi M, Amadori A and Indraccolo S. Side population and cancer stem cells: Therapeutic implications. Cancer Letters. 2010; 288(1):1-9.
5. Wu C and Alman BA. Side population cells in human cancers. Cancer Letters. 2008; 268(1):1-9.
6. Hadnagy A, Gaboury L, Beaulieu R and Balicki D. SP analysis may be used to identify cancer stem cell populations. Experimental Cell Research. 2006; 312(19):3701-3710.
7. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-768.
8. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG. Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+ and ABCG2- Cancer Cells Are Similarly Tumorigenic. Cancer Research. 2005; 65(14):6207-6219.
9. Allen JE, Hart L, Dicker D, Wang W and El-Deiry W. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology and Therapy. 2009; 8(22):2194-2205.
10. Chen AY, Yu C, Bodley A, Peng LF and Liu LF. A New Mammalian DNA Topoisomerase I Poison Hoechst 33342: Cytotoxicity and Drug Resistance in Human Cell Cultures. Cancer Res. 1993; 53(6):1332-1337.
11. Zhao H, Traganos F, Dobrucki J, Wlodkowic D and Darzynkiewicz Z. Induction of DNA damage response by the supravital probes of nucleic acids. Cytometry Part A. 2009; 75A(6):510-519.
12. Chen AY, Yu C, Gatto B and Liu LF. DNA minor groovebinding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proceedings of the National Academy of Sciences. 1993; 90(17):8131-8135.
13. Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010; 12(5):468-476.
14. Le NH, Franken P and Fodde R. Tumour-stroma interactions in colorectal cancer: converging on [beta]- catenin activation and cancer stemness. Br J Cancer. 2008; 98(12):1886-1893.
15. Pang R, Law WL, Chu ACY, Poon JT, Lam CSC, Chow AKM, Ng L, Cheung LWH, Lan XR, Lan HY, Tan VPY, Yau TC, Poon RT and Wong BCY. A Subpopulation of CD26+ Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer. Cell Stem Cell. 2010; 6(6):603- 615.
16. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A and El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 2011; 10(14):2331 - 2338.
17. Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T and Kunz-Schughart LA. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT- 116. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009; 92(3):353-361.
18. Gemei M, Mirabelli P, Di Noto R, Fortunato G and Del Vecchio L. Divergent expression of CD133 in different studies on HCT-116 cell line. International Journal of Cancer. 2011; 128(4):998-1000.
19. Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H and El- Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opinion on Therapeutic Targets. 2012; 0(0):1-14.
20. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W and Kirchner T. Nuclear Overexpression of the Oncoprotein Beta-Catenin in Colorectal Cancer is Localized Predominantly at the Invasion Front. Pathology-Research and Practice. 1998; 194(10):701-704.
21. Horst D, Reu S, Kriegl L, Engel J, Kirchner T and Jung A. The intratumoral distribution of nuclear β-catenin is a prognostic marker in colon cancer. Cancer. 2009; 115(10):2063-2070.
22. Katoh Y and Katoh M. Comparative genomics on PROM1 gene encoding stem cell marker CD133. International Journal of of Molecular Medicine. 2007; 5:967-970.
23. Wielenga VJM, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H and Pals ST. Expression of CD44 in Apc and TcfMutant Mice Implies Regulation by the WNT Pathway. The American Journal of Pathology. 1999; 154(2):515-523.
24. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A and Hirohashi S. Transactivation of the Multidrug Resistance 1 Gene by T-Cell Factor Beta- Catenin Complex in Early Colorectal Carcinogenesis. Cancer Research. 2000; 60(17):4761-4766.
25. Curtin JC and Lorenzi MV. (2010). Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells.
26. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W and El-Deiry WS. The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biology & Therapy. 2009; 8(22):2185-2192.
27. Allen JE and El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports. 2010; 6(4):212-220.
28. Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT and El Deiry WS. Identifying Circulating Tumor Stem Cells That Matter: The Key to Prognostication and Therapeutic Targeting. Journal of Clinical Oncology. 2011; 29(21):2946-2947.
29. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M and Mori M. Clinical Significance of Circulating Tumor Cells, Including Cancer Stem-Like Cells, in Peripheral Blood for Recurrence and Prognosis in Patients With Dukes' Stage B and C Colorectal Cancer. Journal of Clinical Oncology. 2011; 29(12):1547-1555.
30. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou J-Y, Wu GS and El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine. 2013.
31. Hu Y and Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. Journal of Immunological Methods. 2009; 347(1-2):70-78.